Abbott Laboratories $ABT Shares Bought by Intech Investment Management LLC

Key Points

• Intech Investment Management LLC increased its stake in Abbott Laboratories by 5% during the first quarter, owning 117,969 shares worth approximately $15.65 million.
• Abbott Laboratories reported a net margin of 32.43% and a revenue increase of 7.4% year-over-year, reaching $11.14 billion with earnings per share of $1.26.
• The company declared a quarterly dividend of $0.59 per share, representing an annual yield of 1.8% and a payout ratio of 29.57%.

Intech Investment Management LLC boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 117,969 shares of the healthcare product maker's stock after purchasing an additional 5,600 shares during the period. Intech Investment Management LLC's holdings in Abbott Laboratories were worth $15,649,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Kelly Financial Services LLC purchased a new stake in shares of Abbott Laboratories in the first quarter worth $216,000. Bank Pictet & Cie Europe AG grew its stake in shares of Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after buying an additional 2,774 shares during the last quarter. Edge Financial Advisors LLC grew its stake in shares of Abbott Laboratories by 3.3% in the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after purchasing an additional 81 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $84,418,000. Finally, Cerity Partners LLC grew its stake in shares of Abbott Laboratories by 49.8% in the first quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker's stock worth $199,939,000 after purchasing an additional 501,200 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded up $1.27 during trading on Friday, hitting $133.92. 5,700,290 shares of the company's stock were exchanged, compared to its average volume of 4,674,658. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The business has a 50-day simple moving average of $130.41 and a 200-day simple moving average of $131.29. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The stock has a market capitalization of $233.08 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 2.52 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts' consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ABT. Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Wells Fargo & Company cut their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research report on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. BTIG Research cut their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. Finally, Morgan Stanley lifted their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $144.47.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.